[Hinews] AUSTIN, Texas — OrganoidScience, a South Korean biotechnology firm, announced on July 25, 2025, the launch of its U.S. subsidiary, Organoids by Southwest, headquartered in Texas. The July 22 launch marks a strategic expansion into the American market. Departing from the industry’s usual focus on Boston or Silicon Valley, the company has designated Austin and Houston as operational hubs, while its Boston office will continues cultivating East Coast partnerships.

The Texas subsidiary will focus on integrating healthcare technologies and advancing the commercialization of organoid-based therapeutic solutions.

Strategic Bases in Austin and Houston

Austin, already a thriving hub for technology giants like Dell Technologies, Samsung Electronics, Apple, and Tesla, is emerging as a biotechnology and healthcare innovation hub. OrganoidScience is leveraging this environment through collaboration with the University of Texas at Austin’s Dell Medical School and affiliated hospital to study rare and intractable diseases. The company is also in talks with UT professors Audrey Brumback and Ankit Sabharwal for joint research, while exploring partnerships with engineering faculty to advance automation and organ-on-chip technologies. At UT’s Innovation Center, OrganoidScience will set up a research facility to reinforce its academic-industry initiatives.
OrganoidScience commemorates the launch of its Texas subsidiary, expanding its presence in the U.S. organoid therapeutics market. (Photo courtesy of OrganoidScience)
OrganoidScience commemorates the launch of its Texas subsidiary, expanding its presence in the U.S. organoid therapeutics market. (Photo courtesy of OrganoidScience)


In Houston—home to the globally renowned Texas Medical Center—OrganoidScience is targeting leadership in regenerative therapeutics and the commercialization of precision medicine. The company is partnering with institutions such as MD Anderson Cancer Center and Texas Children’s Hospital to broaden the therapeutic indications for its inflammatory bowel disease candidate, ATORM-C..

Advancing Clinical Development

OrganoidScience is also strengthening its ongoing collaboration with Mount Sinai Hospital in New York, leveraging the institution’s expertise in inflammatory bowel disease to expedite U.S. clinical trials for ATORM-C.
Leadership Vision

Kyung-jin Lee, OrganoidScience’s chief technology officer, who oversaw the Texas subsidiary’s launch, underscored the region’s strategic value. “By partnering with Texas’s premier technology and medical infrastructure, we aim to enhance our global competitiveness,” Lee said.

A Platform for Growth

With its Texas launch, OrganoidScience is poised to scale its organoid platforms nationwide—reinforcing its long-term vision to lead in precision medicine and organoid-based therapeutic innovation.

키워드

#오가노이드사이언스
저작권자 © Hinews 무단전재 및 재배포 금지
ad